Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 58

1.

Correlation between paraproteinaemia and viral reactivation after allo-SCT.

Metafuni E, Giammarco S, Bellesi S, Chiusolo P, Laurenti L, Sorà F, Cattani P, Santangelo R, Manzara S, Leone G, Sica S.

Bone Marrow Transplant. 2012 Sep;47(9):1262; author reply 1263. doi: 10.1038/bmt.2012.11. Epub 2012 Feb 13. No abstract available.

PMID:
22327136
[PubMed - indexed for MEDLINE]
2.

Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation.

Medd P, Littlewood S, Danby R, Malladi R, Clifford R, Wareham D, Jeffery K, Ferry B, Roberts D, Peniket A, Littlewood T.

Bone Marrow Transplant. 2011 Jul;46(7):993-9. doi: 10.1038/bmt.2010.244. Epub 2010 Oct 18.

PMID:
20956951
[PubMed - indexed for MEDLINE]
3.

CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath.

Bainton RD, Byrne JL, Davy BJ, Russell NH.

Blood. 2002 Nov 15;100(10):3843-4. No abstract available.

PMID:
12411329
[PubMed - indexed for MEDLINE]
Free Article
4.

Cytomegalovirus retinitis.

Rothova A, de Weerdt O.

Ophthalmology. 2009 Apr;116(4):817-8; author reply 818-9. doi: 10.1016/j.ophtha.2008.12.010. No abstract available.

PMID:
19344836
[PubMed - indexed for MEDLINE]
5.

Increased CMV infection following nonmyeloablative allogeneic stem cell transplantation: a search for the guilty.

Chakrabarti S.

Blood. 2003 Mar 1;101(5):2071. No abstract available.

PMID:
12584145
[PubMed - indexed for MEDLINE]
Free Article
6.

Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.

Satwani P, Baldinger L, Freedman J, Jacobson JS, Guerra J, van de Ven C, Morris E, Garvin J, George D, Bradley MB, Bhatia M, Tallamy B, Schwartz J, Jin Z, Cairo MS.

Biol Blood Marrow Transplant. 2009 Dec;15(12):1587-95. doi: 10.1016/j.bbmt.2009.08.006. Epub 2009 Sep 30.

PMID:
19896083
[PubMed - indexed for MEDLINE]
7.

Late onset cytomegalovirus encephalitis after reduced-intensity conditioning allogeneic SCT: an emerging neurological complication?

Candoni A, Simeone E, Buttignol S, Volpetti S, Lazzarotto T, Pipan C, Fanin R.

Bone Marrow Transplant. 2011 Mar;46(3):455-6. doi: 10.1038/bmt.2010.123. Epub 2010 May 24. No abstract available.

PMID:
20498649
[PubMed - indexed for MEDLINE]
8.

Cytomegalovirus infections following chemotherapies of the newer generation.

Junghanss C.

Haematologica. 2005 Dec;90(12):1591. No abstract available.

PMID:
16330430
[PubMed - indexed for MEDLINE]
9.

Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus.

Liu YC, Lu PL, Hsiao HH, Chang CS, Liu TC, Yang WC, Lin SF.

Ann Hematol. 2012 Apr;91(4):587-95. doi: 10.1007/s00277-011-1351-8. Epub 2011 Oct 15.

PMID:
21997849
[PubMed - indexed for MEDLINE]
10.

Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.

George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.

Transpl Infect Dis. 2010 Aug 1;12(4):322-9. doi: 10.1111/j.1399-3062.2010.00504.x. Epub 2010 May 11.

PMID:
20487414
[PubMed - indexed for MEDLINE]
11.

Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.

Peric Z, Cahu X, Chevallier P, Brissot E, Malard F, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Milpied N, Coste-Burel M, Imbert-Marcille BM, Mohty M.

Leukemia. 2011 Jun;25(6):932-8. doi: 10.1038/leu.2011.26. Epub 2011 Feb 25.

PMID:
21350556
[PubMed - indexed for MEDLINE]
12.

Cytomegalovirus reactivation after matched sibling donor reduced-intensity conditioning allogeneic hematopoietic stem cell transplant correlates with donor killer immunoglobulin-like receptor genotype.

Sobecks RM, Askar M, Thomas D, Rybicki L, Kalaycio M, Dean R, Avery R, Mossad S, Copelan E, Bolwell BJ.

Exp Clin Transplant. 2011 Feb;9(1):7-13.

PMID:
21605017
[PubMed - indexed for MEDLINE]
Free Article
13.

Assessment of disseminated adenovirus infections using quantitative plasma PCR in adult allogeneic stem cell transplant recipients receiving reduced intensity or myeloablative conditioning.

Kalpoe JS, van der Heiden PL, Barge RM, Houtzager S, Lankester AC, van Tol MJ, Kroes AC.

Eur J Haematol. 2007 Apr;78(4):314-21. Epub 2007 Feb 27.

PMID:
17331130
[PubMed - indexed for MEDLINE]
14.

Oral cryotherapy can significantly reduce oral mucositis but not acute GVHD incidence in Flu/Mel conditioning allo-SCT.

Vokurka S, Svoboda T, Jungova A, Karas M, Koza V.

Bone Marrow Transplant. 2012 May;47(5):739-41. doi: 10.1038/bmt.2011.156. Epub 2011 Jul 25. No abstract available.

PMID:
21785473
[PubMed - indexed for MEDLINE]
15.

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.

van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF, van Loon AM, Frassoni F, Bacigalupo A, Schaefer UW, Osterhaus AD, Gratama JW, Löwenberg B, Verdonck LF, Cornelissen JJ.

Blood. 2001 Aug 15;98(4):972-8.

PMID:
11493441
[PubMed - indexed for MEDLINE]
Free Article
16.

Cytomegalovirus-specific CD4 T-cell and glycoprotein B specific antibody response in recipients of allogenic stem cell transplantation.

Ludwig B, Kraus FB, Kipp M, Preiser W, Schwerdtfeger R, Doerr HW, Buxbaum S.

J Clin Virol. 2006 Feb;35(2):160-6. Epub 2005 Aug 19.

PMID:
16112610
[PubMed - indexed for MEDLINE]
17.

Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen.

Mohty M, Mohty AM, Blaise D, Faucher C, Bilger K, Isnardon D, Sainty D, Gastaut JA, Viens P, Olive D, Gaugler B.

Bone Marrow Transplant. 2004 Apr;33(8):839-46.

PMID:
14767500
[PubMed - indexed for MEDLINE]
18.

Advantages and limitations of (non-)myeloablative allogeneic stem cell transplantation.

Huugen D, Schouten HC, Bos GM.

Neth J Med. 2002 May;60(4):162-9. Review.

PMID:
12164394
[PubMed - indexed for MEDLINE]
Free Article
19.

Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia.

Blaise D, Vey N, Faucher C, Mohty M.

Haematologica. 2007 Apr;92(4):533-41. Review.

PMID:
17488664
[PubMed - indexed for MEDLINE]
Free Article
20.

Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.

Gutiérrez-Aguirre CH, Ruiz-Argüelles G, Cantú-Rodríguez OG, González-Llano O, Jaime-Pérez JC, García-Rodríguez F, López-Otero A, Herrera-Garza JL, Gómez-Almaguer D.

Ann Hematol. 2010 Oct;89(10):1045-52. doi: 10.1007/s00277-010-0986-1. Epub 2010 May 21.

PMID:
20490794
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk